Inflammatory Bowel Disease Treatment Market Outlook From 2026 To 2030: Key Growth Factors And Future Opportunities
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Inflammatory Bowel Disease Treatment Market Revenue Growth On Track For A 9.8% CAGR Through 2030
The inflammatory bowel disease treatment market has witnessed significant expansion in recent years. Its valuation is forecast to climb from $27.19 billion in 2025 to $29.8 billion in 2026, advancing at a compound annual growth rate (CAGR) of 9.6%. This historical growth can be linked to the increasing prevalence of ulcerative colitis and Crohn’s disease, enhanced awareness of available IBD treatment options, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early embrace of biologics in more developed areas.
The inflammatory bowel disease treatment market is projected to experience robust expansion over the coming years. Its valuation is set to reach $43.36 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the projection period stems from heightened investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for monitoring patients, increased adoption of biologics and biosimilars, and expanded availability of ibd treatment in developing markets. Significant trends during the forecast period encompass the evolution of personalized ibd therapy, a rise in the application of biologics for treatment, the emergence of minimally invasive drug delivery methods, an increased emphasis on patient adherence initiatives, and the expansion of specialty pharmacies catering to ibd.
Get A Free Sample Report With In-Depth Market Insights:
Inflammatory Bowel Disease Treatment Market Growth Momentum: What Factors Are Shaping Demand?
The increasing incidence of Crohn’s disease and ulcerative colitis is a significant factor propelling the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel diseases (IBD) that lead to inflammation and sores (ulcers) within the digestive tract. The growing number of Crohn’s disease and ulcerative colitis cases is anticipated to heighten the demand for inflammatory bowel disease treatments, as these are widely utilized to alleviate bowel inflammation and to lessen and prevent medical complications. For example, in November 2024, data from the Crohn’s & Colitis Foundation, a US-based Non-profit organization, revealed that approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, which includes both Crohn’s disease and ulcerative colitis. Among this young population, Crohn’s disease is more common, showing a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Thus, the escalating prevalence of Crohn’s disease and ulcerative colitis is expected to drive the growth of the inflammatory bowel disease treatment market.
Inflammatory Bowel Disease Treatment Market Segment Trends And Revenue Contributors
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Inflammatory Bowel Disease Treatment Market Trends Redefining Industry Growth
Companies within the inflammatory bowel disease treatment market are innovating new products, including therapies for moderate to severe active ulcerative colitis, aiming to expand their customer reach, boost sales, and generate higher revenue. These treatments for moderate to severe active ulcerative colitis generally involve pharmaceuticals and, in some cases, surgical procedures. As an example, in October 2023, the US-based pharmaceutical firm, Eli Lilly and Company, disclosed that the U. S. Food and Drug Administration (FDA) had approved Omvoh (mirikizumab-mrkz). This product, offered as both an infusion (300 mg/15 mL) and an injection (100 mg/mL), stands as the first and only interleukin-23p19 (IL-23p19) antagonist developed to address moderately to severely active ulcerative colitis (UC) in adults. Omvoh is engineered to target the p19 subunit of IL-23, thereby inhibiting the IL-23 pathway, which is a key driver of the inflammation central to UC’s progression. The therapeutic approach for Omvoh commences with three 300-mg IV infusions, given once a week every four weeks, followed by a maintenance stage consisting of two 100-mg subcutaneous self-injections administered every four weeks.
Inflammatory Bowel Disease Treatment Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
View The Full Inflammatory Bowel Disease Treatment Market Report:
Inflammatory Bowel Disease Treatment Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
